Improving global manufacturing processes Innovation in processes across our global manufacturing network can have a considerable impact on the efficiency of our business. One such focus area has been on Ig yield improvements. This will be critical to our goal of improving margins. To drive Horizon 1 improvements, CSL is focused on enhancing process robustness and improving Ig recoveries by optimising existing processes. CSL continues to pursue incremental, continuous process improvement initiatives with a mindset geared towards year‑on‑year Ig yield growth within our current regulatory filing boundaries. Key strategies include leveraging data analytics, optimising processes, refining plasma allocation strategies, and fostering operational excellence. These efforts have already started to yield positive results this year, and CSL anticipates continued benefits in the coming years. Global Manufacturing Presence Across our three businesses, we own and operate highly advanced manufacturing facilities. CSL Vifor St. Gallen, Switzerland CSL Seqirus Holly Springs NC, US Liverpool, UK Parkville, Australia Waltham MA, US CSL Behring Broadmeadows, Australia Bern, Switzerland Kankakee IL, US Marburg, Germany Wuhan, China 31
RkJQdWJsaXNoZXIy MjE2NDg3